anonymous
Guest
anonymous
Guest
Of course you have to go to Cafepharma to get this important company news. No communicatios from leadership.
Individoir tumbles 20% after US court ruling on generic rival
March 23, 2018 8:08 am by Federica Cocco
The British pharmaceuticals group Indivior plunged 20 per cent on Friday after disclosing that a US court ruled that a generic drug developed by America’s Alvogen does not infringe on three of its patents.
The dispute centres on the opioid addiction treatment Suboxone — the trade name for buprenorphine and naloxone. Alvogen is seeking to sell generic versions of the drug.
Indivior said that if the Food and Drug Administration approves Alvogen’s treatment, “it would be able to market a generic alternative to Suboxone Film in the US.”
The group, which spun out of Reckitt Benckiser in 2014, has been engaged in a series of legal cases and patent and antitrust litigation with several pharmaceutical companies.
Shaun Thaxter, Indivior chief executive, said: "We will appeal this ruling and continue to vigorously defend our intellectual property.”
He added that “we remain confident in Indivior's long-term outlook and vision.”
Individoir tumbles 20% after US court ruling on generic rival
March 23, 2018 8:08 am by Federica Cocco
The British pharmaceuticals group Indivior plunged 20 per cent on Friday after disclosing that a US court ruled that a generic drug developed by America’s Alvogen does not infringe on three of its patents.
The dispute centres on the opioid addiction treatment Suboxone — the trade name for buprenorphine and naloxone. Alvogen is seeking to sell generic versions of the drug.
Indivior said that if the Food and Drug Administration approves Alvogen’s treatment, “it would be able to market a generic alternative to Suboxone Film in the US.”
The group, which spun out of Reckitt Benckiser in 2014, has been engaged in a series of legal cases and patent and antitrust litigation with several pharmaceutical companies.
Shaun Thaxter, Indivior chief executive, said: "We will appeal this ruling and continue to vigorously defend our intellectual property.”
He added that “we remain confident in Indivior's long-term outlook and vision.”